The immunocytokine PD1-IL2v overcomes immune checkpoint resistance, and combination with an anti-PD-L1 antibody further enhances its anti-tumor activity.-MedSci.cn

The immunocytokine PD1-IL2v overcomes immune checkpoint resistance, and combination with an anti-PD-L1 antibody further enhances its anti-tumor activity.

Wullschleger, S; Tichet, M; Codarri-Deak, L; Umana, P; Klein, C; Hanahan, D

CANCER RESEARCH, 2021; 81 (13):

科室
- - 订阅+
  - 更多科室
工具
服务